Brief: Lantern Pharma & Starlight Therapeutics Present LP-184
26/11/2024 13:46
Nov 26 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA & STARLIGHT THERAPEUTICS PRESENT LP-184
(STAR-001) PHASE 1B TRIAL DESIGN AND PRECLINICAL DATA IN
GLIOBLASTOMA AT SOCIETY FOR NEURO-ONCOLOGY (SNO) 2024
HIGHLIGHTING NOVEL SYNTHETIC LETHALITY
Source text: ID:nBw352z2ma
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview